Transdermal drug delivery co kickstarts $5.7m series A:
This article was originally published in Clinica
Ruggell, Liechtenstein-based drug delivery company Pantec Biosolutions is initiating a SwFr6.3m ($5.67m) series A financing, which will be led by Austrian VC Gamma Capital Partners. Pantec intends to use the funds to advance the development of its laser microporation device LEDDT (laser easy drug delivery technology). The system is designed to deliver transdermally large molecular weight compounds, such as hormones used for in vitro fertilisation (IVF) therapy. Current IVF regimes consist of daily injections of hormones over a period of several weekends.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.